288261-49-4

Upstream product

• 288261-48-3 1,2-3,4-5,6-tri-O-isopropylidene-L-iditol 
• 288261-51-8 2,5-di-O-benzyl-1,6-di-O-dimethoxytriphenylmethyl-3,4-O-isopropylidene-L-iditol 
• 288261-50-7 1,6-di-O-dimethoxytriphenylmethyl-3,4-O-isopropylidene-L-iditol 
• 94925-98-1 3,4-O-methylethylidene-D-mannitol 
• 214139-57-8 2,5-di-O-benzyl-3,4-O-isopropylidene-L-iditol 

Downstream Products

• 214139-61-4 N₁,N₆-di[2-methyl-1S-(methylcarbamoyl)propyl]-2R,5R-dibenzyloxy-3S,4S-dihydroxy-3,4-O-iso-thiocarbonylhexanediamide 
• 214139-60-3 N₁,N₆-di[2-methyl-1S-(methylcarbamoyl)propyl]-2R,5R-dibenzyloxy-3S,4S-dihydroxy hexanediamide 
• 214139-59-0 N₁,N₆-di[2-methyl-1S-(methylcarbamoyl)propyl]-2R,5R-dibenzyloxy-3S,4S-dihydroxy-3,4-O-iso-propylidenehexanediamide 

Relevant academic research and scientific papers

Impact of the central hydroxyl groups on the activity of symmetrical HIV-1 protease inhibitors derived from L-mannaric acid

The influence of the central hydroxyl groups on the anti-viral activity of symmetrical HIV-1 protease inhibitors derived from L-mannaric acid has been examined. L-Iditol was synthesized and used as a chiral precursor for the synthesis of the corresponding inhibitor with inverted configuration at C-3 and C-4. Key intermediates were 3,4-O-isopropylidene-L-iditol and the activated L-idaric acid succinimidyI ester. The configurations of the central hydroxyl groups required for optimal inhibition of the HIV-1 protease were determined to be the C-3R and C-4R, i.e. the L-manno-configuration. Three C2-symmetric inhibitors were converted to their thiocarbonates and reduced to provide the corresponding hydroxyethyl transition-state mimics. Deletion of the C-4 hydroxyl group in these inhibitors gave no further improvement in the anti-viral activity. (C) 2000 Published by Elsevier Science Ltd.